15 June 2016 in Oncology Letters
The roles of alternative splicing and RNA editing in gene regulation and transcriptome diversity are well documented. Adenosine deaminases acting on RNA (ADARs) are responsible for adenosine-to-inosine (A-to-I) editing and exemplify the complex association between RNA editing and alternative splicing. The self-editing activity of ADAR2, which acts on its own pre-mRNA, leads to its alternative splicing. Alternative splicing occurs independently at nine splicing sites on ADAR2 pre-mRNA, generating numerous alternative splicing variants with various catalytic activities. A-to-I RNA editing is important in a range of physiological processes in humans and is associated with several diseases, including amyotrophic lateral sclerosis, mood disorders, epilepsy and glioma. Reduced editing at the glutamine/arginine site of the AMPA receptor subunit GluA2 in glioma, without any alteration in ADAR2 expression, is a notable phenomenon. Several studies have tried to explain this alteration in the catalytic activity of ADAR2; however, the underlying mechanism remains unclear. The present review summarizes the relevant literature and shares experimental results concerning ADAR2 alternative splicing. In particular, the present review demonstrates that shifts in the relative abundance of the active and inactive splicing variants of ADAR2 may reduce the ADAR2 editing activity in glioma. Dominant expression of ADAR2 splicing variant with low enzyme activity causes reduced RNA editing of GluA2 subunit at the glutamine/arginine site in glioma.
24 December 2013 in Oncology Letters
β‑diketone‑cobalt complexes, a family of newly synthesized non‑platinum metal compounds, exhibit potential antitumor activity; however, the antitumor mechanism is unclear. The current study investigated the mechanism by which β‑diketone‑cobalt complexes inhibit rat C6 glioma cell proliferation. It was found that β‑diketone‑cobalt complexes suppress rat C6 glioma cell viability in a dose‑dependent manner (3.125‑100 µg/ml). In rat C6 glioma cells, the IC50 value of β‑diketone‑cobalt complexes was 24.7±3.395 µg/ml and the IC10 value was 4.37±1.53 µg/ml, indicating a strong inhibitory effect. Further investigation suggested that β‑diketone‑cobalt complexes inhibit rat C6 glioma cell proliferation, which is associated with S‑phase arrest and DNA synthesis inhibition. During this process, β‑diketone‑cobalt complexes decreased cyclin A expression and increased cyclin E and p21 expression. In addition, β‑diketone‑cobalt complexes exhibit a stronger antitumor capability than the antineoplastic agent, 5‑fluorouracil.
17 January 2025 in Science Advances
The body weight–based thrombolytic medication strategy in clinical trials shows critical defects in recanalization rate and post-thrombolysis hemorrhage. Methods for perceiving thrombi heterogeneity of thrombolysis resistance is urgently needed for precise thrombolysis. Here, we revealed the relationship between the thrombin heterogeneity and the thrombolysis resistance in thrombi and created an artificial biomarker-based nano-patrol system with robotic functional logic to perceive and report the thrombolysis resistance of thrombi. The nano-patrols are contrallable and are able to accomplish thrombolysis resistance-matched personalized and precise therapy according to the feedback signal from artificial biomarkers. This nano-patrol system depicted more enhanced thrombolytic efficiency (elevated by 25%) than alteplase for mini pig model and clinical thrombi and achieved recanalization in thrombotic model where alteplase encountered failure. Moreover, the nano-patrol remarkably reduced the infarct volume and the hemorrhagic transformation risk (0.12-fold of alteplase) of cerebral thrombosis. Therefore, we developed a unique tool for diagnosing thrombolysis resistance and achieving personalized and precise thrombolysis.
5 February 2024 in Composites Part B: Engineering
1 February 2012 in Neurosurgery Quarterly
A 40-year-old Chinese woman presented with a cystic mass (size of 23×23×27 mm, volume 7.9 cm3) with tumor nodule in the pons. The patient received initial gamma knife surgery (GKS) treatment of dose 18.0 Gy, and the mass increased in volume to 12.8 cm3 after 7 weeks. Stereotactic aspiration surgery of the intratumoral cyst was performed, yielding 10.5 mL of yellowish-white fluid; biopsy confirmed the diagnosis of glioma. A second GKS of dose 10.5 Gy was performed 1 week later. Follow-up magnetic resonance imaging revealed a cyst volume of 1.0 cm3, with an obvious decrease in size of the tumor nodule at 18 months after the second GKS. The patient is alive and well 36 months after the combined therapy. To the best of our knowledge, cystic brainstem glioma treated by repeat gamma knife treatment combined with stereotactic aspiration surgery in a single patient has not been reported previously in the English-language literature. The findings of this case suggest that cyst drainage by stereotactic aspiration surgery can improve the effect of GKS for small brainstem glioma, even if the diameter of tumor is less than 30 mm.
14 June 2021 in Chinese Journal of Hematology